S
Secretome Therapeutics
Biotech & Life Sciences · Dallas, United States · Founded 2018
Developing the stem cell secretome and focus on onconephrology MoreLess
Secretome Therapeutics is pioneering the development of secretome-based therapies, focusing on the anti-inflammatory and pro-mitochondrial properties of stem cell secretions. The company operates in the biopharmaceutical sector, specifically targeting onconephrology, which deals with kidney-related issues in cancer patients. Their flagship product, STM 21, aims to mitigate the inflammatory toxicities associated with cancer treatments. Secretome Therapeutics serves healthcare providers and patients undergoing cancer treatment. The business model revolves around research and development, clinical trials, and eventual commercialization of their secretome-based therapies. Revenue is generated through product sales, partnerships, and potentially licensing agreements.
Keywords: secretome, stem cells, cancer treatment, onconephrology, anti-inflammatory, pro-mitochondrial, biopharmaceutical, STM 21, healthcare, clinical trials.
Company overview
Secretome Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Dallas, United States
- Employees
- 17
- Open positions
- 2
- Dealroom signal
- 48.4
Valuation & funding
Secretome Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | May 2026 | $30M | $120M | RA Capital Management | ↗ |
| GRANTOther financing | Mar 2026 | $250K | — | Parent Project Muscular Dystrophy | ↗ |
| LATE VCOther financing | Nov 2024 | $20M | $82M | Undisclosed | ↗ |
| GROWTH EQUITY VCOther financing | Sep 2024 | $1.8M | — | HEST Investments | ↗ |
| EARLY VCOther financing | Feb 2023 | $6.9M | $28M | Undisclosed | ↗ |
| SPINOUTOther financing | Jan 2018 | University of Maryland Baltimore County | — |
Growth signals
Secretome Therapeutics website traffic
Latest recorded traffic for Secretome Therapeutics is 1.6K monthly website visits, up 60% over the last three months. Secretome Therapeutics's team grew 13.3% over the past year.
Comparisons
Secretome Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Secretome Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Secretome Therapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Secretome Therapeutics has talent and traffic
team presence
In the news
Latest news about Secretome Therapeutics
Recent press, funding announcements, and product moves mentioning Secretome Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Secretome Therapeutics
An AI-synthesized read of the highest-engagement posts about Secretome Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Secretome Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.